Cancer Genetics Inc. [NASDAQ: CGIX] gained 4.08% on the last trading session, reaching $5.36 price per share at the time. The company report on March 25, 2021 that Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX.
Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Cancer Genetics, Inc. (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. (“StemoniX”).
Cancer Genetics Inc. represents 10.56 million in outstanding shares, while the company has a total market value of $54.67 million with the latest information. CGIX stock price has been found in the range of $5.20 to $7.25.
If compared to the average trading volume of 2.27M shares, CGIX reached a trading volume of 8337323 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cancer Genetics Inc. [CGIX]:
Maxim Group have made an estimate for Cancer Genetics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 07, 2017. The new note on the price target was released on June 27, 2017, representing the official price target for Cancer Genetics Inc. stock. Previously, the target price had yet another raise to $6, while The Benchmark Company analysts kept a Speculative Buy rating on CGIX stock.
The Average True Range (ATR) for Cancer Genetics Inc. is set at 0.86, with the Price to Sales ratio for CGIX stock in the period of the last 12 months amounting to 8.68. The Price to Book ratio for the last quarter was 2.60, with the Price to Cash per share for the same quarter was set at 0.11.
Trading performance analysis for CGIX stock
Cancer Genetics Inc. [CGIX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.38. With this latest performance, CGIX shares dropped by -10.37% in over the last four-week period, additionally plugging by 39.22% over the last 6 months – not to mention a rise of 87.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CGIX stock in for the last two-week period is set at 45.81, with the RSI for the last a single of trading hit 40.81, and the three-weeks RSI is set at 48.68 for Cancer Genetics Inc. [CGIX]. The present Moving Average for the last 50 days of trading for this stock 5.36, while it was recorded at 5.90 for the last single week of trading, and 3.85 for the last 200 days.
Cancer Genetics Inc. [CGIX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Cancer Genetics Inc. [CGIX] shares currently have an operating margin of -37.14 and a Gross Margin at +49.34. Cancer Genetics Inc.’s Net Margin is presently recorded at -94.25.
Return on Total Capital for CGIX is now -18.71, given the latest momentum, and Return on Invested Capital for the company is -92.20. Return on Equity for this stock declined to -97.06, with Return on Assets sitting at -27.37. When it comes to the capital structure of this company, Cancer Genetics Inc. [CGIX] has a Total Debt to Total Equity ratio set at 33.49. Additionally, CGIX Total Debt to Total Capital is recorded at 25.09, with Total Debt to Total Assets ending up at 16.59. Long-Term Debt to Equity for the company is recorded at 5.00, with the Long-Term Debt to Total Capital now at 3.74.
Reflecting on the efficiency of the workforce at the company, Cancer Genetics Inc. [CGIX] managed to generate an average of -$62,591 per employee. Receivables Turnover for the company is 1.89 with a Total Asset Turnover recorded at a value of 0.29.Cancer Genetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.60.
Cancer Genetics Inc. [CGIX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Cancer Genetics Inc. posted -4.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3,592.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CGIX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cancer Genetics Inc. go to 40.00%.
An analysis of insider ownership at Cancer Genetics Inc. [CGIX]
There are presently around $2 million, or 5.40% of CGIX stock, in the hands of institutional investors. The top three institutional holders of CGIX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 242,801, which is approximately 25.543% of the company’s market cap and around 7.49% of the total institutional ownership; ACADIAN ASSET MANAGEMENT LLC, holding 47,067 shares of the stock with an approximate value of $0.25 million in CGIX stocks shares; and BLACKROCK INC., currently with $0.2 million in CGIX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Cancer Genetics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 7 institutional holders increased their position in Cancer Genetics Inc. [NASDAQ:CGIX] by around 125,194 shares. Additionally, 4 investors decreased positions by around 1,039 shares, while 2 investors held positions by with 258,044 shares. The mentioned changes placed institutional holdings at 384,277 shares, according to the latest SEC report filing. CGIX stock had 3 new institutional investments in for a total of 40,165 shares, while 2 institutional investors sold positions of 1,002 shares during the same period.